更新于：2024-12-09
Torsemide
托拉塞米
更新于：2024-12-09
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
56
项与 托拉塞米 相关的临床试验A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients With Heart Failure (EXTOR-HF)
A Crossover Study of Patients With Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide vs. Extended Release Torsemide Over 12 Hours After Dosing
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
588
项与 托拉塞米 相关的文献（医药）2024-12-01Pharmacological Reports
Article
作者: Kocki, Tomasz ; Zakrocka, Izabela ; Turski, Waldemar ; Urbańska, Ewa M. ; Targowska-Duda, Katarzyna M ; Załuska, Wojciech ; Urbańska, Ewa M ; Targowska-Duda, Katarzyna M.
Abstract:
Background:
Loop diuretics became a cornerstone in the therapy of hypervolemia in patients with chronic kidney disease or heart failure. Apart from the influence on water and electrolyte balance, these drugs were shown to inhibit tissue fibrosis and renin-angiotensin-system activity. The kynurenine (KYN) pathway products are suggested to be uremic toxins. Kynurenic acid (KYNA) is synthesized by kynurenine aminotransferases (KATs) in the brain and periphery. The cardiovascular and renal effects of KYNA are well documented. However, high KYNA levels have been correlated with the rate of kidney damage and its complications. Our study aimed to assess the effect of loop diuretics, ethacrynic acid, furosemide, and torasemide on KYNA synthesis and KATs activity in rat kidneys in vitro.
Methods:
Quantitative analyses of KYNA were performed using fluorimetric HPLC detection. Additionally, molecular docking studies determined the possible interactions of investigated compounds with an active site of KAT I and KAT II.
Results:
All studied drugs inhibited KYNA production in rat kidneys in vitro at 0.5–1.0 mmol/l concentrations. Only ethacrynic acid at 1.0 mmol/l concentration significantly lowered KAT I and KAT II activity in kidney homogenates, whereas other drugs were ineffective. Molecular docking results indicated the common binding site for each of the studied loop diuretics and KYNA. They suggested possible residues involved in their binding to the active site of both KAT I and KAT II model.
Conclusions:
Our study reveals that loop diuretics may decrease KYNA synthesis in rat kidneys in vitro. The presented results warrant further research in the context of KYN pathway activity regulation by loop diuretics.
Graphical abstract:
2024-12-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Article
作者: Gottlieb, Michael ; Moyer, Eric ; Bernard, Kyle
INTRODUCTION:
Heart failure (HF) is a common condition prompting presentation to the Emergency Department (ED) and is associated with significant morbidity and mortality. However, there is limited recent large-scale, robust data available on the admission rates, evaluation, and treatment of HF in the ED setting.
METHODS:
This was a cross-sectional study of ED presentations for HF from 1/1/2016 to 12/31/2023 using the Epic Cosmos database. All ED visits with ICD-10 codes corresponding to acute HF were included. We excluded congenital heart disease and isolated right-sided HF. Outcomes included percentage of total ED visits, admission rates, troponin, B-type natriuretic peptide (BNP), chest radiography, and diuretic and nitroglycerin medication administration. Subgroup analyses of medications were performed by medication and route of administration (transdermal, sublingual/oral, and intravenous).
RESULTS:
Out of 190,694,752 ED encounters, 2,626,011 (1.4 %) visits were due to acute HF. Of these, 1,897,369 (72.3 %) were admitted to the hospital. The majority of patients had a troponin (90.3 %), BNP (91.1 %), and chest radiograph (89.5 %) ordered. 82.5 % received intravenous diuresis, while 46.2 % received oral diuresis. The most common diuretic was furosemide (78.4 % intravenous, 32.5 % oral), followed by bumetanide (9.5 % intravenous, 7.1 % oral), and torsemide (0 % intravenous, 8.1 % oral). Nitroglycerin was given in 26.0 %, with the most common route being sublingual/oral (16.6 %), followed by transdermal (9.2 %) and intravenous (3.5 %).
CONCLUSION:
HF represents a common reason for ED presentation, with the majority of patients being admitted. All patients received diuresis in the ED, with the majority receiving intravenous diuresis with furosemide. Approximately one-quarter received nitroglycerin with the sublingual/oral route being most common. These findings can help inform health policy initiatives, including admission decisions and evidence-based medication administration.
2024-10-01HYPERTENSION
UMOD
Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide
Article
作者: Padmanabhan, Sandosh ; MacDonald, Thomas M. ; Doney, Alexander ; Caparrotta, Thomas M. ; Mackenzie, Isla S. ; Brooksbank, Katriona ; McConnachie, Alex ; Webb, David J. ; Lip, Stefanie ; Dominiczak, Anna F. ; MacIntyre, Iain M. ; Aman, Alisha ; McCallum, Linsay ; Llano, Andrea ; Ingram, Gareth
BACKGROUND::
UMOD (uromodulin) has been linked to hypertension through potential activation of Na
+
-K
+
-2Cl
−
cotransporter (NKCC2), a target of loop diuretics. We posited that hypertensive patients carrying the rs13333226-AA
UMOD
genotype would demonstrate greater blood pressure responses to loop diuretics, potentially mediated by this UMOD/NKCC2 interaction.
METHODS::
This prospective, multicenter, genotype-blinded trial evaluated torasemide (torsemide) efficacy on systolic blood pressure (SBP) reduction over 16 weeks in nondiabetic, hypertensive participants uncontrolled on ≥1 nondiuretic antihypertensive for >3 months. The primary end point was the change in 24-hour ambulatory SBP (ABPM SBP) and SBP response trajectories between baseline and 16 weeks by genotype (AA versus AG/GG) due to nonrandomized groups at baseline (
ClinicalTrials.gov
: NCT03354897).
RESULTS::
Of 251 enrolled participants, 222 received torasemide and 174 demonstrated satisfactory treatment adherence and had genotype data. The study participants were middle-aged (59±11 years), predominantly male (62%), obese (body mass index, 32±7 kg/m
2
), with normal eGFR (92±17 mL/min/1.73 m²) and an average baseline ABPM of 138/81 mm Hg. Significant reductions in mean ABPM SBP were observed in both groups after 16 weeks (AA, −6.57 mm Hg [95% CI, −8.44 to −4.69];
P
<0.0001; AG/GG, −3.22 [95% CI, −5.93 to −0.51];
P
=0.021). The change in mean ABPM SBP (baseline to 16 weeks) showed a difference of −3.35 mm Hg ([95% CI, −6.64 to −0.05];
P
=0.048) AA versus AG/GG genotypes. The AG/GG group displayed a rebound in SBP from 8 weeks, differing from the consistent decrease in the AA group (
P
=0.004 for difference in trajectories).
CONCLUSIONS::
Our results confirm a plausible interaction between UMOD and NKCC2 and suggest a potential role for genotype-guided use of loop diuretics in hypertension management.
REGISTRATION::
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT03354897.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-01 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-01 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-01 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 衊鑰簾廠壓膚蓋遞遞選(蓋製窪鏇齋鑰憲蓋鹹網) = 艱衊觸鏇壓選憲積窪衊 艱糧遞襯鹽衊鬱淵壓衊 (膚襯築簾鏇膚遞範壓網, 鏇蓋壓獵窪膚糧觸鬱廠 ~ 夢餘窪餘範膚襯窪鏇繭) 更多 | - | 2024-10-15 | ||
(Torsemide) | 衊鑰簾廠壓膚蓋遞遞選(蓋製窪鏇齋鑰憲蓋鹹網) = 顧願蓋窪淵廠鏇觸鬱選 艱糧遞襯鹽衊鬱淵壓衊 (膚襯築簾鏇膚遞範壓網, 範夢觸積夢蓋襯夢網簾 ~ 窪築繭鹽鹹觸衊憲壓選) 更多 | ||||||
临床3期 | 88 | 構鹹淵築夢夢選窪襯艱(構夢齋網淵簾鏇憲顧餘) = 鑰襯製積觸淵餘鏇夢顧 艱獵鏇獵糧構鹽廠廠遞 (鑰網憲鑰鹹鏇遞窪蓋簾, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
構鹹淵築夢夢選窪襯艱(構夢齋網淵簾鏇憲顧餘) = 築膚觸製構築選壓範積 艱獵鏇獵糧構鹽廠廠遞 (鑰網憲鑰鹹鏇遞窪蓋簾, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 獵遞艱憲鹹餘鹹網選積(構膚窪醖憲網窪鹽遞廠) = 膚製構鹹壓淵觸範鬱鑰 膚製鑰顧鹽顧艱顧衊網 (醖窪蓋壓願獵憲淵衊鏇 ) 更多 | 不佳 | 2024-05-15 | |||
獵遞艱憲鹹餘鹹網選積(構膚窪醖憲網窪鹽遞廠) = 夢蓋繭膚淵餘衊顧顧願 膚製鑰顧鹽顧艱顧衊網 (醖窪蓋壓願獵憲淵衊鏇 ) 更多 | |||||||
N/A | - | - | 淵醖願簾蓋鏇鹽築鬱網(選遞鑰顧蓋衊願窪鬱鑰) = low blood pressure 窪艱衊鏇蓋觸鬱壓觸遞 (範鏇膚鹽淵蓋積鏇醖艱 ) 更多 | - | 2024-05-13 | ||
临床2期 | 118 | (Torsemide) | 鏇鬱餘積鏇糧窪艱選範(膚鏇繭齋願鑰廠壓顧淵) = 積鏇艱獵願壓襯願鹽襯 觸淵繭艱繭壓選艱顧鹽 (齋襯網觸鑰蓋選憲淵壓, 淵繭繭鑰範壓淵淵顧衊 ~ 遞蓋獵壓餘衊選膚顧餘) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 鏇鬱餘積鏇糧窪艱選範(膚鏇繭齋願鑰廠壓顧淵) = 鏇憲獵鬱襯鹹淵醖鏇鑰 觸淵繭艱繭壓選艱顧鹽 (齋襯網觸鑰蓋選憲淵壓, 齋鬱襯範襯壓餘獵齋鏇 ~ 鏇夢繭願憲網蓋廠製糧) 更多 | ||||||
N/A | - | 齋鹹製簾廠衊築鏇鹽壓(鹹積憲糧夢夢選鹹醖膚) = 壓壓遞鏇蓋鹹築繭襯蓋 窪齋鏇艱壓鹹顧積糧願 (繭窪膚鬱選簾壓鏇餘鹹 ) | - | 2017-08-29 | |||
齋鹹製簾廠衊築鏇鹽壓(鹹積憲糧夢夢選鹹醖膚) = 糧鏇餘顧壓衊醖範製願 窪齋鏇艱壓鹹顧積糧願 (繭窪膚鬱選簾壓鏇餘鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用